Key Points
- COO Christine Zedelmayer sold 120,312 shares on March 13 at $2.50 each for $300,780, leaving her with 62,586 shares (a 65.78% drop in her ownership); this follows several recent large sales (181,219 on Mar 9; 185,937 on Feb 19; 100,000 on Dec 23), signaling substantial insider liquidation.
- Equillium shares opened at $2.32, trade in a one‑year range of $0.27–$2.70 with a $141.3M market cap, and carry a mixed analyst record (2 Buy, 2 Hold, 1 Sell) with a MarketBeat consensus rating of Hold and an average target price of $6.00.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 120,312 shares of Equillium stock in a transaction on Friday, March 13th. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00. Following the sale, the chief operating officer owned 62,586 shares in the company, valued at $156,465. This represents a 65.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Christine Zedelmayer also recently made the following trade(s):
- On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total transaction of $362,438.00.
- On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The stock was sold at an average price of $1.76, for a total value of $327,249.12.
- On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total value of $150,000.00.
Equillium Stock Performance
EQ opened at $2.32 on Tuesday. Equillium, Inc. has a one year low of $0.27 and a one year high of $2.70. The stock has a market capitalization of $141.26 million, a P/E ratio of -3.74 and a beta of 1.80. The business's 50-day simple moving average is $1.55 and its 200-day simple moving average is $1.42.
Wall Street Analysts Forecast Growth
Several research analysts have commented on EQ shares. Zacks Research raised Equillium to a "hold" rating in a research report on Thursday, February 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Equillium in a research report on Monday, December 29th. Stifel Nicolaus began coverage on shares of Equillium in a report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 target price on the stock. Wall Street Zen upgraded shares of Equillium from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Roth Mkm started coverage on shares of Equillium in a research note on Friday. They set a "buy" rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Equillium has a consensus rating of "Hold" and an average target price of $6.00.
Get Our Latest Research Report on EQ
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of EQ. ADAR1 Capital Management LLC increased its holdings in shares of Equillium by 0.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company's stock valued at $8,693,000 after purchasing an additional 48,090 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Equillium during the fourth quarter worth $9,057,000. Balyasny Asset Management L.P. lifted its holdings in shares of Equillium by 3.6% during the fourth quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company's stock worth $3,218,000 after purchasing an additional 72,602 shares during the period. Cantor Fitzgerald L. P. grew its position in Equillium by 32.4% in the 4th quarter. Cantor Fitzgerald L. P. now owns 562,643 shares of the company's stock valued at $872,000 after buying an additional 137,643 shares during the last quarter. Finally, Diadema Partners LP grew its position in Equillium by 15.8% in the 4th quarter. Diadema Partners LP now owns 347,393 shares of the company's stock valued at $538,000 after buying an additional 47,393 shares during the last quarter. 27.05% of the stock is currently owned by hedge funds and other institutional investors.
Equillium Company Profile
(
Get Free Report)
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
